400
Participants
Start Date
March 31, 2003
Zevalin (ibritumomab tiuxetan)
Rituxan (rituximab)
Biogen Idec Incorporated, San Diego
Research Site, Huntsville
Research Site, Scottsdale
Research Site, Little Rock
Research Site, Bakersfield
Research Site, Concord
Research Site, Duarte
Research Site, Loma Linda
Research Site, Los Angeles
Research Site, Mission Viejo
Research Site, Newport Beach
Research Site, Orange
Research Site, Sacramento
Research Site, San Diego
Research Site, Santa Barbara
Research Site, Vallejo
Research Site, Farmington
Research Site, Newark
Research Site, Jacksonville
Research Site, Lakeland
Research Site, Boise
Research Site, Coeur d'Alene
Research Site, Aurora
Research Site, Chicago
Research Site, Evanston
Research Site, Harvey
Research Site, Maywood
Research Site, Urbana
Research Site, Indianapolis
Research Site, Munster
Research Site, Kansas City
Research Site, Baltimore
Research Site, Boston
Research Site, Ann Arbor
Research Site, Detroit
Research Site, Flint
Research Site, Royal Oak
Research Site, Saint Joseph
Research Site, Minneapolis
Research Site, Rochester
Research Site, Jackson
Research Site, Tupelo
Research Site, Columbia
Research Site, Kansas City
Research Site, St Louis
Research Site, Albuquerque
Research Site, Farmington
Research Site, Buffalo
Research Site, Manhasset
Research Site, New York
Research Site, The Bronx
Research Site, Bismarck
Research Site, Cleveland
Research Site, Toledo
Research Site, Portland
Research Site, Philadelphia
Research Site, Pittsburgh
Research Site, Charleston
Research Site, Greenville
Research Site, Nashville
Research Site, Houston
Research Site, Lubbock
Research Site, Temple
Research Site, Salt Lake City
Research Site, Bremerton
Research Site, Morgantown
Research Site, Wausau
Lead Sponsor
Biogen
INDUSTRY